Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Asciminib and Trastuzumab for Women with Metastatic HER2 Positive (HER2+) Breast Cancer with Brain Metastases

A Single Arm, Open-label Phase Ib/II Study of Asciminib in HER2+ Breast Cancer Brain Metastases (ASCENdANT)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of asciminib (Scemblix®) combined with trastuzumab (Herceptin®) in treating breast cancer that has spread to the brain.

Who is this for?: Women with metastatic (stage IV) HER2 positive (HER2+) breast cancer that has spread to the brain (brain metastases). You must have at least one brain metastasis that is new or has grown. You must have received at least one prior treatment for metastatic breast cancer, including T-DXd and tucatinib (unless you could not take these due to allergies or side effects). You must be receiving care at Duke University in Durham, North Carolina. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Asciminib (Scemblix®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain.</li> <li class="seamTextUnorderedListItem">Asciminib (Scemblix®) is a targeted therapy that blocks a protein called ABL kinase, which may help cancer cells grow and spread. </li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®)is a targeted therapy that attaches to the HER2 protein on cancer cells to help stop them from growing. </li> <li class="seamTextUnorderedListItem">Researchers are studying whether asciminib (Scemblix®) combined with trastuzumab (Herceptin®) is safe and can help treat breast cancer that has spread to the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07136428' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/types-breast-cancer/metastatic-breast-cancer/brain-metastases?utm_source=ppc&utm_medium=search&utm_campaign=metastatic&utm_id=journey&gad_source=1&gad_campaignid=22665917977&gbraid=0AAAAAoX38tB4ofAVAUZ1cLkRgyVjvg9-' target='_blank'>Living Beyond Breast Cancer: Metastatic breast cancer to the brain</a> </li></ul>
1

Asciminib and Trastuzumab for Women with Metastatic HER2 Positive (HER2+) Breast Cancer with Brain Metastases

A Single Arm, Open-label Phase Ib/II Study of Asciminib in HER2+ Breast Cancer Brain Metastases (ASCENdANT)
Icon

Nearest Location from 94107:
2385 miles
Duke University
Durham, NC

Icon

Visits:
About 1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT07136428

Icon

Phase I-II

HELP GUIDE